Jan Kaiserle

Families and clinicians have long wrestled with the same question: when choices span medication, therapy, and a dozen hopeful alternatives, which option is most likely to help right now without creating new problems later, and how confident should anyone be in that promise. That recurring

Jan Kaiserle sits down with Ivan Kairatov, a biopharma expert deeply versed in molecular therapeutics and translational research, to discuss a new approach to overcoming treatment resistance in neuroblastoma. Drawing on work published in Science Advances in 2025, Kairatov explains how a failed

Ivan Kairatov is a biopharma expert with a track record bridging preclinical discovery and translational development across oncology subtypes. He has worked at the interface of receptor biology, pharmacology, and clinical trial design, and he brings a pragmatic lens to drug repurposing. In this

Imagine a silent epidemic affecting thousands of men each year, often undetected until it’s too late, with societal norms discouraging open conversations about personal health challenges, and prostate cancer standing as the most common cancer among men in the UK, with around 55,000 new cases

Imagine a scenario where a patient, battling cancer that has spread to the brain, undergoes complex treatments like radiation or chemotherapy, only to face uncertainty when follow-up scans can’t clearly show whether the tumor is growing or if the changes are just treatment side effects. This

Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.

In the rapidly advancing world of biotechnology and medicine, protein engineering stands as a cornerstone for innovation, yet it faces persistent challenges in designing proteins with precise, tailored functionalities that meet specific needs. For years, scientists have wrestled with the

The alarming statistic that individuals with type 1 diabetes face a 4.29-fold increased risk of developing bladder cancer has sent ripples through the medical community, challenging long-held assumptions about the intersection of metabolic disorders and malignancies. With bladder cancer already

Imagine a world where a doctor’s visit is just a click away, no matter where a patient resides or what time of day it is—telehealth has turned this vision into reality for millions across the globe, reshaping how medical services are accessed. This transformative approach breaks down barriers of

What happens when the building blocks of life face destruction before they can fulfill their purpose, and how do cells protect these vital components during such a delicate process? Inside every cell, a precise mechanism unfolds where proteins, essential for everything from immunity to growth, are